We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Lab Technology Will Boost Cell Therapy Applications

By LabMedica International staff writers
Posted on 25 Nov 2013
Print article
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
A newly released family of cell culture systems was designed specifically to support and advance the growing field of cell therapy.

The Xuri Cell Expansion System W25 is the first member of GE Healthcare's (Chalfont St. Giles, United Kingdom) new hi-tech cell culture systems to be released for sale.

This system comprises a reliable and intuitive device for expansion of human cell cultures for cellular therapy purposes. It employs single-use, functionally closed disposables to minimize risk of contamination. The Xuri system can accommodate working volumes from as little as one liter—appropriate for growing high-density cell cultures—with room to expand up to 25 liters. The system is based on GE Healthcare's WAVE rocking technology that provides mixing and aeration. The Xuri system is functionally closed, which minimizes the risk of cell contamination while allowing the culture to reach high cell densities.

The Xuri Cell Expansion System W25 is enhanced by sensors to monitor the cell culture environment and is operated via "UNICORN" control software. The system was designed to deliver reliable and accurate performance for research, process development, or manufacturing operations.

Eric Roman, general manager of research and applied markets at GE Healthcare, said, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, (Stockholm, Sweden) to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable, and efficient progress of cell therapies from clinical development to commercialization.”

Related Links:

GE Healthcare
Karolinska University Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.